2023
Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI
Abu-Much A, Grines C, Batchelor W, Maini A, Zhang Y, Redfors B, Bellumkonda L, Bharadwaj A, Moses J, Truesdell A, Li Y, Baron S, Lansky A, Basir M, Cohen D, O'Neill W. Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI. American Heart Journal 2023, 269: 139-148. PMID: 38151142, DOI: 10.1016/j.ahj.2023.12.015.Peer-Reviewed Original ResearchBaseline LV ejection fractionLV ejection fractionPercutaneous coronary interventionPCI-related complicationsLV dysfunctionEjection fractionLV functionLeft main percutaneous coronary interventionHigh-risk percutaneous coronary interventionHigh-risk PCI patientsImmediate percutaneous coronary interventionMain percutaneous coronary interventionModerate LV dysfunctionSevere LV dysfunctionVentricular systolic dysfunctionVentricular ejection fractionCoronary complicationsLVEF groupMACCE rateCerebrovascular eventsPCI patientsSystolic dysfunctionCoronary interventionIII studyMyocardial infarctionTCT-214 Right Ventricular Function in Patients Undergoing Impella-Assisted High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study
Rommel K, Bonnet G, Bellumkonda L, Zhang Y, Lansky A, Redfors B, Granada J, Bharadwaj A, Basir B, Patel R, O’Neill W, Burkhoff D. TCT-214 Right Ventricular Function in Patients Undergoing Impella-Assisted High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study. Journal Of The American College Of Cardiology 2023, 82: b82-b83. DOI: 10.1016/j.jacc.2023.09.221.Peer-Reviewed Original ResearchTCT-145 Relationship Between Preprocedural Blood Pressure and Outcomes in Patients Undergoing Impella-Supported High-Risk PCI: Insights From the cVAD PROTECT III Study
Bonnet G, Rommel K, Falah B, Lansky A, Zhang Y, Schonning M, Redfors B, Burkhoff D, Cohen D, Patel R, Basir B, O’Neill W, Granada J. TCT-145 Relationship Between Preprocedural Blood Pressure and Outcomes in Patients Undergoing Impella-Supported High-Risk PCI: Insights From the cVAD PROTECT III Study. Journal Of The American College Of Cardiology 2023, 82: b56-b57. DOI: 10.1016/j.jacc.2023.09.151.Peer-Reviewed Original ResearchImpella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study
Abu-Much A, Maini A, Grines C, Bharadwaj A, Moses J, Zhang Y, Redfors B, Bellumkonda L, Li Y, Truesdell A, Baron S, Lansky A, Basir M, O'Neill W. Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study. Cardiovascular Revascularization Medicine 2023, 53: s126. DOI: 10.1016/j.carrev.2023.05.290.Peer-Reviewed Original ResearchSex Differences in pLVAD-Assisted High-Risk Percutaneous Coronary Intervention Insights From the PROTECT III Study
Shah T, Abu-Much A, Batchelor W, Grines C, Baron S, Zhou Z, Li Y, Maini A, Redfors B, Hussain Y, Wollmuth J, Basir M, O'Neill W, Lansky A. Sex Differences in pLVAD-Assisted High-Risk Percutaneous Coronary Intervention Insights From the PROTECT III Study. JACC Cardiovascular Interventions 2023, 16: 1721-1729. PMID: 37409991, DOI: 10.1016/j.jcin.2023.04.036.Peer-Reviewed Original ResearchConceptsHigh-risk percutaneous coronary interventionFemale patientsIII studySex-based differencesImmediate PCISYNTAX scoreClinical outcomesMyocardial infarctionStroke/transient ischemic attackWorse renal functionAcute limb ischemiaTransient ischemic attackSex differencesPercutaneous coronary interventionAcute myocardial infarctionHigher ejection fractionCause deathCoronary complicationsIschemic attackMajor bleedingNonfemoral accessPercutaneous CoronaryPrior strokeCerebrovascular eventsVascular complicationsC-2 | Association of Pre-Procedural SYNTAX Score With Outcomes After Impella-Assisted High Risk Percutaneous Coronary Intervention – Results from the PROTECT III Study
Baron S, Faraz H, Zhang Y, Bharadwaj A, Osborn E, Abu Much A, Lansky A, Basir M, Moses J, O'Neill W, Grines C. C-2 | Association of Pre-Procedural SYNTAX Score With Outcomes After Impella-Assisted High Risk Percutaneous Coronary Intervention – Results from the PROTECT III Study. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100787. DOI: 10.1016/j.jscai.2023.100787.Peer-Reviewed Original ResearchCRT-700.05 Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study
Abu-Much A, Maini A, Grines C, Bharadwaj A, Moses J, Zhang Y, Redfors B, Bellumkonda L, Li Y, Truesdell A, Baron S, Lansky A, Basir M, O'Neill W. CRT-700.05 Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study. JACC Cardiovascular Interventions 2023, 16: s107. DOI: 10.1016/j.jcin.2023.01.337.Peer-Reviewed Original Research
2022
Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices
O'Neill WW, Anderson M, Burkhoff D, Grines CL, Kapur NK, Lansky AJ, Mannino S, McCabe JM, Alaswad K, Daggubati R, Wohns D, Meraj PM, Pinto DS, Popma JJ, Moses JW, Schreiber TL, Ohman E. Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices. American Heart Journal 2022, 248: 139-149. PMID: 35192839, DOI: 10.1016/j.ahj.2022.02.006.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionHigh-risk percutaneous coronary interventionPROTECT IIProTECT IIICoronary interventionDepressed LVEFIII studyIII patientsMyocardial infarctionStroke/transient ischemic attackTransient ischemic attackCompleteness of revascularizationPrior myocardial infarctionKaplan-Meier analysisDuration of supportHospital bleedingMACCE rateProcedural hypotensionCause mortalityCerebrovascular eventsIschemic attackJeopardy scorePrior CABGSYNTAX scoreHospital discharge
2020
Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study
Adams G, Shammas N, Mangalmurti S, Bernardo NL, Miller WE, Soukas PA, Parikh SA, Armstrong EJ, Tepe G, Lansky A, Gray WA. Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study. Journal Of Endovascular Therapy 2020, 27: 473-480. PMID: 32242768, PMCID: PMC7288854, DOI: 10.1177/1526602820914598.Peer-Reviewed Original ResearchConceptsPeripheral artery diseasePeripheral intravascular lithotripsyIntravascular lithotripsyResidual stenosisAcute gainObservational studyChronic limb-threatening ischemiaSingle-arm observational studyBalloon-based technologiesHigher acute gainMean residual stenosisLimb-threatening ischemiaLower limb arteriesEnd of procedureSevere arterial calcificationLow residual stenosisReal-world studyAngiographic complicationsDistal embolizationHospital dischargeIII studyArtery diseaseThrombotic eventsEndovascular treatmentLimb arteries
2010
A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.
Seth A, Serruys PW, Lansky A, Hermiller J, Onuma Y, Miquel-Hebert K, Yu S, Veldhof S, Sood P, Sudhir K, Stone GW. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. EuroIntervention 2010, 5: 788-94. PMID: 20142192, DOI: 10.4244/eijv5i7a132.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPaclitaxelProsthesis DesignRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentRisk FactorsSex FactorsSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsTAXUS paclitaxel-eluting stentTarget vessel failureAngiographic late lossLate lossDiameter stenosisIII studyPooled analysisSPIRIT IIAdverse cardiac eventsSegment late lossStent late lossCoronary artery diseaseEES groupCardiac eventsArtery diseaseFemale patientsPES groupPatient levelClinical dataXIENCE VStent typeTwo-year analysisWomen
2002
Predictors of radiation failure after treatment of in-stent restenosis with gamma vascular brachytherapy: pooled analysis from GAMMA I, II, and SCRIPPS III studies
Limpijankit T, Abizaid A, Mehran R, Lansky A, Dangas G, Kipshidze N, Stone G, Collins M, Moses J, Leon M, Teirstein P. Predictors of radiation failure after treatment of in-stent restenosis with gamma vascular brachytherapy: pooled analysis from GAMMA I, II, and SCRIPPS III studies. Journal Of The American College Of Cardiology 2002, 39: 46. DOI: 10.1016/s0735-1097(02)80196-6.Peer-Reviewed Original Research